18F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Gabriel Martínez, Leon Flicker, Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Marta Roqué i Figuls, Gerard Urrútia, Xavier Bonfill Cosp

Producció científica: Contribució a una revistaArticle de revisióRecercaAvaluat per experts

21 Cites (Scopus)

Resum

© 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the diagnostic test accuracy (DTA) of the 18F PET ligands for Aβ (18F-Florbetapir, 18F-Florbetaben, and 18F-Flutemetamol) as the index tests for detecting participants with mild cognitive impairment (MCI) at baseline who would clinically progress to Alzheimer's disease dementia (ADD), or other forms of non-ADD, or any form of dementia at follow-up. To investigate the heterogeneity of the DTA in the included studies, we will evaluate the spectrum of people, referral centres, clinical criteria of MCI, 18F PET ligands for Aβ (18F-Florbetapir, 18F-Florbetaben, and 18F-Flutemetamol) techniques, reference standards used, duration of follow-up, aspects of study quality, and conflicts of interest.
Idioma originalEnglish
Número d’articleCD012216
RevistaCochrane Database of Systematic Reviews
Volum2016
Número5
DOIs
Estat de la publicacióPublicada - 30 de maig 2016

Fingerprint

Navegar pels temes de recerca de '18F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)'. Junts formen un fingerprint únic.

Com citar-ho